|
| INTRO EQUATIONS CRITERIA DECISION CONVERT SPECIALTIES REFS SEARCH NEW FHIR APP POLICIES CONTACT |
| Progressive Multifocal Leukoencephalopathy (PML) Risk in patients Treated with Natalizumab |
The EBMcalc module Progressive Multifocal Leukoencephalopathy (PML) Risk in patients Treated with Natalizumab is available in EBMcalc Complete Edition.
This Decision TreeCalc evaluates the following decision points:
- JC virus antibodies
- Was there prior immunosuppresant use
- Natalizumab exposure time
Decision Tree end points include:
- PML incidence ≤0.09 / 1000 with 95% confidence interval of 0 to 0.48
- PML incidence 0.56 / 1000 with 95% confidence interval of 0.36 to 0.83
- PML incidence 4.6 / 1000 with 95% confidence interval of 3.7 to 5.6
- PML incidence 1.6 / 1000 with 95% confidence interval of 0.91 to 2.6
- PML incidence 11.1 / 1000 with 95% confidence interval of 8.3 to 14.5
- PML incidence 0.31 / 1000 with 95% confidence interval of 0.2 to 0.45
- PML incidence 2.5 / 1000 with 95% confidence interval of 2.1 to 3.1
- PML incidence 0.88 / 1000 with 95% confidence interval of 0.5 to 1.4
- PML incidence 6.1 / 1000 with 95% confidence interval of 4.6 to 8
References
- Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 May 17;366(20):1870-80. PubMed ID: 22591293
- Tur C, Montalban X. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs. 2014 Jul;28(7):641-8. PubMed ID: 24942634
Legal Notices and Disclaimer All information contained in and produced by the EBMcalc system is provided for educational purposes only. This information should not be used for the diagnosis or treatment of any health problem or disease. THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER. EBMcalc is NOT a medical device. Click here for full notice and disclaimer. |